Patent Description:
<NPL> concerns possible plans for development of Cubicin.

The cephalosporin (6R,7R)-<NUM>-[<NUM>-Amino-<NUM>-[<NUM>-(<NUM>-aminoethyl)ureido]-<NUM>-methyl-<NUM>-pyrazol-<NUM>-ium-<NUM>-ylmethyl]-<NUM>-[<NUM>-(<NUM>-amino-<NUM>,<NUM>,<NUM>-thiadiazol-<NUM>-yl)-<NUM>-[(Z)-<NUM>-carboxy-<NUM>-methylethoxyimino]acetamido]-<NUM>-cephem-<NUM>-carboxylic acid (also referred to as "CXA-<NUM>" and previously designated FR264205) is an antibacterial agent. CXA-<NUM> can be provided as the compound shown in <FIG>. The antibacterial activity of CXA-<NUM> is believed to result from its interaction with penicillin binding proteins (PBPs) to inhibit the biosynthesis of the bacterial cell wall which acts to stop bacterial replication. CXA-<NUM> can be combined (e.g., mixed) with a β-lactamase inhibitor ("BLI"), such as tazobactam. Tazobactam is a BLI against Class A and some Class C β-lactamases, with well established in vitro and in vivo efficacy in combination with active β-lactam antibiotics. The combination of CXA-<NUM> and tazobactam in a <NUM>:<NUM> weight ratio is an antibiotic pharmaceutical composition ("CXA-<NUM>") for parenteral administration. CXA-<NUM> displays potent antibacterial activity in vitro against common Gram-negative and selected Gram-positive organisms. CXA-<NUM> is a broad-spectrum antibacterial with in vitro activity against Enterobacteriaceae including strains expressing extended spectrum β-lactamases-resistant (MIC<NUM> = <NUM>µg/mL), as well as Pseudomonas aeruginosa (P. aeruginosa) including multi-drug resistant strains (MIC<NUM>= <NUM>µg/mL). CXA-<NUM> is a combination antibacterial with activity against many Gram-negative pathogens known to cause intrapulmonary infections, including nosocomial pneumonia caused by P. aeruginosa.

Intrapulmonary infections, such as nosocomial pneumonia, remain a major cause of morbidity and mortality, especially infections caused by drug resistant pathogens such as P. aeruginosa. One challenge in treating intrapulmonary infections with systemic administration of an antibiotic is determining the antibiotic dose that will provide a therapeutically safe and effective concentration of the antibiotic at the site of an infection on the mucosal side of the bronchi in the lung (i.e., in the bronchial secretions). Many antibiotics diffuse poorly from the bloodstream across the bronchi [e.g., <NPL>)], which can result in the administration of higher doses of antibiotic than would be prescribed for a truly systemic infection. Furthermore, the purulent sputum that characterizes infected patients tends to compromise the potency of many antibiotics (See e.g., <NPL>)). In some cases, the result is the prescription of large amounts of a systemically administered antibiotic to treat an intrapulmonary infection.

The efficacy of an antibiotic depends in part on the concentration of the drug at the site of action. Efficacy of antimicrobial therapy requires adequate antibiotic concentrations at the site of bacterial infection, and some authorities believe that epithelial lining fluid (ELF) concentrations are a reasonable surrogate for predicting effective concentrations for treating intrapulmonary infections such as pneumonia. For many antibiotics, clinical data correlating ELF concentrations to clinical outcome is unavailable and the clinical significance of differences in pulmonary penetration of antibiotics is unknown or poorly characterized. Few studies have quantified the penetration of β-lactam agents into the lung, as measured by the ratio of area under the concentration-time curve (AUC) in ELF to AUC in plasma (AUC(ELF)/AUC(plasma) ratio). For some published studies, the concentration of antibiotics measured in the ELF of the lung has varied widely. For example, the reported penetration ratio of telavancin in healthy human volunteers ranges widely between <NUM> and <NUM> (<NPL>). Thus, predicting the penetration of a drug into the ELF a priori, based on the structure, molecular weight, size and solubility is difficult due to the limited data available on the effect of physicochemical properties on the lung penetration of drugs.

Accordingly, the efficacy of a particular drug in treating intrapulmonary infections, in particular nosocomial pneumonia, cannot be predicted solely on the basis of data, such as in vitro data relating to the activity of that drug against a particular bacterium, which does not give any indication as whether the drug will accumulate at a therapeutically safe and effective concentration at the site of an infection on the mucosal side of the bronchi in the lung (i.e., in the bronchial secretions). For instance, tigicycline, a glycylcycline antimicrobial, has in vitro activity against many species of Gram-positive and Gram-negative bacteria, including P. aeruginosa, and it has been approved by the FDA for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community acquired pneumonia. However, tigicycline is not approved for the treatment of nosocomial pneumonia, in view of an increased mortality risk associated with the use of tigicycline compared to other drugs in patients treated for nosocomial pneumonia.

The present invention provides ceftolozane (CXA-<NUM>) and tazobactam in a <NUM>:<NUM> (ceftolozane:tazobactam) weight ratio at a dose of <NUM> for use in a method of treating nosocomial pneumonia caused by Gram-negative pathogens in a human, wherein the ceftolozane and tazobactam is administered intravenously once every <NUM> hours, and wherein the ceftolozane is in its free-base form or in its salt form. The invention is based in part on results from a human clinical study designed to assess the ELF penetration of CXA-<NUM> in comparison to piperacillin/tazobactam, indicated for the treatment of nosocomial pneumonia. The study described herein quantified the penetration of CXA-<NUM> into the lung, as measured by the ratio of area under the concentration-time curve (AUC) in epithelial lining fluid (ELF) to AUC in plasma (AUC(ELF)/AUC(plasma) ratio). The results of the study indicate that CXA-<NUM> penetrated into the ELF of human patients, with a ceftolozane ELF/plasma AUC ratio of <NUM>. The measured ELF concentrations of ceftolozane exceeded <NUM>µg/mL for <NUM>% of the <NUM>-hour dosing interval, a concentration that is predicted to inhibit <NUM>% of Pseudomonas aeruginosa based on current surveillance data.

The study showed that CXA-<NUM> penetrated well into the ELF of healthy volunteers compared to piperacillin/tazobactam, an agent widely used for treatment of lower respiratory infections. The intrapulmonary pharmacokinetics measured in the study supports the use of CXA-<NUM> as a parenteral (e.g., intravenous) antibiotic for treatment of intrapulmonary infections, such as nosocomial pneumonia or other lower respiratory tract infections.

The present invention relates to ceftolozane (CXA-<NUM>) and tazobactam in a <NUM>:<NUM> (ceftolozane:tazobactam) weight ratio at a dose of <NUM> for use in the treatment of nosocomial pneumonia caused by Gram-negative pathogens in a human, wherein the ceftolozane and tazobactam is administered intravenously once every <NUM> hours, and wherein the ceftolozane is in its free-base form or in its salt form. As used herein, the term "ceftolozane" means CXA-<NUM> in a free-base or salt form, preferably a hydrogen sulfate form (illustrated in <FIG>). In one embodiment, ceftolozane is CXA-<NUM> in its free-base form. In another embodiment, ceftolozane is CXA-<NUM> in its salt form, preferably a hydrogen sulfate form.

Ceftolozane (in free base or salt form, preferably hydrogen sulfate form) and tazobactam are in a <NUM>:<NUM> (ceftolozane:tazobactam) weight ratio. Provided herein are ceftolozane and tazobactam for use in methods of treating nosocomial pneumonia as defined by the claims. Ceftolozane hydrogen sulfate and tazobactam are in a <NUM>:<NUM> weight ratio. The combination of ceftolozane hydrogen sulfate and tazobactam in a <NUM>:<NUM> weight ratio is referred to herein and in the examples as "CXA-<NUM>.

The invention provides ceftolozane and tazobactam for use in a method of treating an intrapulmonary infection as defined in the claims. The method comprises administering ceftolozane in combination with tazobactam.

The invention comprises administering CXA-<NUM> and the infection comprises Gram-negative bacteria.

In one embodiment, the amount of the ceftolozane in the ELF of the subject effective to treat an intrapulmonary infection is at least about <NUM>µg/ml. The ELF concentration of ceftolozane in the ELF may reach at least about <NUM>µg/ml after administration of ceftolozane (CXA-<NUM>) and tazobactam as defined by the claims. The subject is a human having nosocomial pneumonia. The subject (or patient) may, in some embodiments, have ventilator acquired pneumonia or hospital acquired pneumonia.

In the invention, the intrapulmonary infection is nosocomial pneumonia. The intrapulmonary infection may comprise Pseudomonas aeruginosa, Enterobacteriaceae, or a combination thereof. Typically, the intrapulmonary infection comprises Pseudomonas aeruginosa. The intrapulmonary infection may comprise a pathogen with minimum inhibitory concentration for CXA-<NUM> of ≤ 8µg/ml. The intrapulmonary infection may comprise a pathogen with minimum inhibitory concentration for ceftolozane of ≤ 8µg/ml.

In another aspect, the invention provides ceftolozane, for use in a method of treating an intrapulmonary infection as defined by the claims. The ceftolozane is intravenously administered. The ceftolozane is administered once every <NUM> hours as an infusion. In some embodiments, the ceftolozane is intravenously administered as a <NUM>-minute infusion.

In one embodiment, the ceftolozane is for use in a method of treating an intrapulmonary infection as defined in the claims. The ceftolozane is for use in a method of treating nosocomial pneumonia. The intrapulmonary infection may comprise Pseudomonas aeruginosa, Enterobacteriaceae, or a combination thereof. Typically, the intrapulmonary infection comprises Pseudomonas aeruginosa. The intrapulmonary infection may comprise a pathogen with minimum inhibitory concentration for ceftolozane and tazobactam of ≤ 8µg/ml. The intrapulmonary infection may comprise a pathogen with minimum inhibitory concentration for ceftolozane of ≤ 8µg/ml.

The invention also provides ceftolozane, for use in a method of treating an intrapulmonary infection, comprising administration of ceftolozane in combination with tazobactam as defined in the claims. The ceftolozane and tazobactam are intravenously administered. The ceftolozane and tazobactam are administered once every <NUM> hours as an infusion. In some embodiments, the ceftolozane and/or tazobactam is intravenously administered as a <NUM>-minute infusion. Both the ceftolozane and tazobactam are intravenously administered. In some embodiments, both the ceftolozane and tazobactam are administered once every <NUM> hours as an infusion. In some embodiments, both the ceftolozane and tazobactam are intravenously administered as a <NUM>-minute infusion. The ceftolozane is for use in a method of treating an intrapulmonary infection as defined in the claims. The ceftolozane is for use in a method of treating nosocomial pneumonia. The intrapulmonary infection may comprise Pseudomonas aeruginosa, Enterobacteriaceae, or a combination thereof. Typically, the intrapulmonary infection comprises Pseudomonas aeruginosa. The intrapulmonary infection may comprise a pathogen with minimum inhibitory concentration for ceftolozane and tazobactam of ≤ 8µg/ml. The intrapulmonary infection may comprise a pathogen with minimum inhibitory concentration for ceftolozane of ≤ 8µg/ml.

In another aspect, the invention provides tazobactam, for use in a method of treating an intrapulmonary infection, comprising administration of tazobactam in combination with ceftolozane as defined in the claims. The tazobactam and ceftolozane is intravenously administered. In some embodiments, the tazobactam and ceftolozane is administered once every <NUM> hours as an infusion. In some embodiments, the tazobactam and/or ceftolozane is intravenously administered as a <NUM>-minute infusion. Both the tazobactam and ceftolozane are intravenously administered. Both the tazobactam and ceftolozane are administered about once every <NUM> hours as an infusion. In another embodiments, both the tazobactam and ceftolozane are intravenously administered as a <NUM>-minute infusion.

The tazobactam is for use in a method of treating an intrapulmonary infection as defined in the claims. The tazobactam is for use in a method of treating nosocomial pneumonia as defined in the claims. The intrapulmonary infection may comprise Pseudomonas aeruginosa, Enterobacteriaceae, or a combination thereof. Typically, the intrapulmonary infection comprises Pseudomonas aeruginosa. The intrapulmonary infection may comprise a pathogen with minimum inhibitory concentration for ceftolozane and tazobactam of ≤ 8µg/ml. The intrapulmonary infection may comprise a pathogen with minimum inhibitory concentration for ceftolozane of ≤ 8µg/ml.

In another aspect, the invention provides ceftolozane and tazobactam, as a combined preparation for simultaneous, separate or sequential use in a method of treating an intrapulmonary infection as defined in the claims. The ceftolozane and tazobactam are intravenously administered. In some embodiments, the ceftolozane and tazobactam are administered once every <NUM> hours as an infusion. In some embodiments, the ceftolozane and tazobactam, are intravenously administered as a <NUM>-minute infusion.

In one embodiment, the ceftolozane and tazobactam are for use in a method of treating an intrapulmonary infection as defined in the claims. The intrapulmonary infection is nosocomial pneumonia. The intrapulmonary infection may comprise Pseudomonas aeruginosa, Enterobacteriaceae, or a combination thereof. Typically, the intrapulmonary infection comprises Pseudomonas aeruginosa. The intrapulmonary infection may comprise a pathogen with minimum inhibitory concentration for ceftolozane and tazobactam of ≤ 8µg/ml. The intrapulmonary infection may comprise a pathogen with minimum inhibitory concentration for ceftolozane of ≤ 8µg/ml.

Ceftolozane is administered in combination with tazobactam, e,g, CXA-<NUM> is administered. <NUM> of ceftolozane and tazobactam is administered every <NUM> hours. In one embodiment, the amount of the ceftolozane in the ELF of the subject effective to treat an intrapulmonary infection is at least about <NUM>µg/ml. The ELF concentration of ceftolozane in the ELF may reach at least about <NUM>µg/ml after administration of the ceftolozane. The subject is a human having nosocomial pneumonia. The subject (or patient) may, in some embodiments, have ventilator acquired pneumonia or hospital acquired pneumonia.

The safe and effective treatment of intrapulmonary infection with CXA-<NUM> includes administration of an amount of the CXA-<NUM> selected to provide a therapeutically effective dose of the CXA-<NUM> antibiotic in the epithelial lining fluid (ELF). The penetration of CXA-<NUM> into the ELF compared to a piperacillin/tazobactam comparator was assessed in a Phase <NUM> clinical study in healthy adult volunteers. The piperacillin/tazobactam comparator contained piperacillin/tazobactam in an <NUM>:<NUM> weight ratio with a total of <NUM> mEq of sodium per gram of piperacillin, FDA approved under the tradename ZOSYN® ("Zosyn"). The study results evaluate the penetration of intravenously administered CXA-<NUM> into healthy human lungs, as measured by the ratio of area under the concentration-time curve (AUC) in epithelial lining fluid (ELF) to AUC in plasma (AUC(ELF)/AUC(plasma) ratio).

In the study, a <NUM> amount of piperacillin/tazobactam incorporates the same dose of tazobactam (<NUM>) as <NUM> of CXA-<NUM>. A multiple-dose regimen was used in this study to ensure that the concentrations of the analytes reached steady-state in both plasma and ELF prior to assessment. Healthy volunteers were chosen to standardize the subject population and minimize the variability associated with using actively ill patients. The objectives of the study included: (<NUM>) determination and comparison of the ELF to plasma concentration ratios of multiple-doses of intravenous CXA-<NUM> compared to piperacillin/tazobactam in healthy adult volunteers, and (<NUM>) assessment of the safety and tolerability of multiple-doses of intravenous CXA-<NUM> in healthy adult volunteers.

The study was a Phase <NUM> prospective, randomized (<NUM>:<NUM>), comparator controlled, open-label study of <NUM> healthy adult volunteers. Each healthy volunteer received <NUM> doses of either CXA-<NUM>(<NUM> grams every <NUM> hours as a <NUM>-minute infusion) or piperacillin/tazobactam (<NUM> grams every <NUM> hours as a <NUM>-minute infusion). Subjects received <NUM> doses of a study drug, underwent serial blood draws at planned plasma sampling timepoints, and underwent a single bronchoalveolar lavage (BAL) procedure at one of the scheduled timepoints (Table <NUM>).

A total of <NUM> subjects were enrolled; <NUM> in the CXA-<NUM> group and <NUM> in the piperacillin/tazobactam group. Key Inclusion Criteria for the study were: (<NUM>) healthy adult male or non-pregnant females between <NUM> and <NUM> years, inclusive; (<NUM>) body mass index between <NUM> and <NUM>; and (<NUM>) forced Expiratory Volume in <NUM> second (FEV1) ≥ <NUM>%. Key Exclusion Criteria for the study were: (<NUM>) pregnancy or lactation; (<NUM>) clinically significant systemic disease or the existence of any surgical or medical condition that may have interfered with the distribution, metabolism, or excretion of CXA-<NUM>; (<NUM>) history of asthma or any restrictive or obstructive lung disease; (<NUM>) history of smoking or abuse of narcotics or alcohol; (<NUM>) positive test for human immunodeficiency virus, Hepatitis B surface antigen, or Hepatitis C antibodies; (<NUM>) any condition or situation where bronchoscopy was not advisable; and (<NUM>) impairment of renal function (CrCl < <NUM>/min).

Plasma and BAL datapoints were used to construct one concentration-time profile in the ELF using the mean concentrations at each time point. After dosing, a single ELF sample was obtained by bronchoalveolar lavage (BAL) from each healthy volunteer at one of <NUM> scheduled time points (<NUM> subjects/time point/treatment group). The ELF to plasma concentrations of multiple-doses was determined. Serial plasma samples were collected pre- and post-treatment over a <NUM>-hour (piperacillin/tazobactam) or <NUM>-hour (CXA-<NUM>) time period. Urea levels in the plasma and BAL were used to calculate the ELF drug concentrations (see Table <NUM>). Pharmacokinetic parameters for ELF were calculated by non-compartmental analysis using the mean concentrations at each time point. The intrapulmonary penetration of CXA-<NUM> into the ELF was determined by dividing the ELF AUC<NUM>-t by mean plasma AUC<NUM>-t.

The concentration of CXA-<NUM> and piperacillin/tazobactam in ELF were estimated from the concentration of drug in BAL fluid, the volume of BAL fluid collected, and the ratio of urea concentration in BAL fluid to that in plasma. Calculation of ELF volume was determined by the urea dilution method, using urea as an endogenous marker of ELF recovered by BAL. Concentration of CXA-<NUM> and piperacillin/tazobactam in ELF was estimated from the concentration of drug in BAL fluid, the volume of BAL fluid collected, and the ratio of urea concentration in BAL fluid to that in plasma. The following formulas represent these calculations: <MAT>.

[CXA/T]BAL is the concentration of CXA-<NUM> in BAL fluid; VBAL is the volume of aspirated BAL fluid (total); VELF is VBAL × [urea]BAL/[urea]plasma, where [urea]BAL is the concentration of urea in the BAL fluid (supernatant) and [urea]plasma is the concentration of urea in the plasma specimens.

[PIP/T]BAL is the concentration of piperacillin/tazobactam in BAL fluid; VBAL is the volume of aspirated BAL fluid (total); VELF is VBAL × [urea]BAL/[urea]plasma, where [urea]BAL is the concentration of urea in the BAL fluid (supernatant) and [urea]plasma is the concentration of urea in the plasma specimens.

No oral antibiotic therapy was permitted. Safety was monitored through the review of vital signs, laboratory and physical examinations and the occurrence of adverse events (AEs). Subjects who received three doses of study medication and had both BAL and plasma samples collected were included in the pharmacokinetic (PK) analysis population. All randomized subjects who received any dose (including partial doses) of study medication were included in the safety analysis population.

The results of the study (Table <NUM>) indicate that CXA-<NUM> penetrated well into ELF. The ceftolozane component of CXA-<NUM> ELF/plasma AUC ratio was <NUM>, compared to <NUM> for the piperacillin component of piperacillin/tazobactam. The ELF concentrations of ceftolozane exceeded <NUM>µg/mL for <NUM>% of the <NUM>-hour dosing interval. The plasma concentrations for ceftolozane were consistent with those seen previously at this dose.

The ELF concentration vs. time profiles for ceftolozane and tazobactam components of CXA-<NUM> are shown in <FIG> and <FIG>, respectively. Comparative data showing the ELF concentration vs. time profiles for piperacillin and tazobactam components of the comparator drug are shown in <FIG> and <FIG>, respectively. The ELF to plasma penetration ratios are shown in Table <NUM>.

The PK parameters were determined by non-compartmental PK analysis. PHOENIX® WinNonlin v <NUM> (PHARSIGHT®, Mountain View, California) was used for the derivation of all PK individual measures for each subject. The PK parameters for ELF were calculated by taking the mean concentrations of the <NUM> subjects at each time point and constructing a single profile over the duration of sampling. In the event that the urea concentrations determined in plasma or ELF were below quantifiable limits, thereby providing only an estimate of concentration, those values were not used in the calculation of mean concentration at that time point. The ceftolozane, piperacillin, and tazobactam PK parameters that were computed in plasma and ELF were:.

The ELF/plasma AUC ratio for the ceftolozane component of CXA-<NUM> was <NUM>, compared to <NUM> for the piperacillin component of the comparator drug (piperacillin/tazobactam). The ELF/plasma AUC ratio for tazobactam was <NUM> and <NUM> when given as part of CXA-<NUM> and piperacillin/tazobactam, respectively. The ELF concentrations of ceftolozane exceeded <NUM>µg/mL for <NUM>% of the <NUM>-hour dosing interval. The plasma and ELF concentrations of tazobactam when given as piperacillin/tazobactam was approximately <NUM>-fold higher than when an equivalent dose was given as CXA-<NUM>.

The results show that ceftolozane and tazobactam (i.e., administered as CXA-<NUM>) penetrated well into the ELF of healthy volunteers compared to piperacillin/tazobactam, an agent widely used for treatment of lower respiratory infections. CXA-<NUM>'s intrapulmonary pharmacokinetics support use of CXA-<NUM> as a parenteral (e.g., intravenous) antibiotic for treatment of lower respiratory tract infections, including infections caused by pathogens with minimum inhibitory concentrations of ≤ 8µg/ml. The concentrations of ceftolozane in ELF exceeded <NUM>µg/mL, a concentration that inhibits <NUM>% of P. aeruginosa, for approximately <NUM>% of the <NUM>-hour dosing interval for the CXA-<NUM> regimen of <NUM> grams every eight hours as a <NUM> minute infusion.

Among the subjects, <NUM> of the <NUM> (<NUM>%) subjects received all <NUM> doses of study medication and completed the BAL procedure. One subject prematurely discontinued piperacillin/tazobactam and terminated their participation in the study due to an AE of hypersensitivity that occurred during administration of the first dose. Demographics and baseline characteristics are summarized in Table <NUM>, the two treatment arms were well balanced.

During the study, treatment-emergent AEs (TEAEs) occurred in <NUM>% (<NUM>/<NUM>) of subjects receiving CXA-<NUM> and <NUM>% (<NUM>/<NUM>) of subjects receiving piperacillin/tazobactam. No serious AEs were reported in either treatment group. All AEs were mild in severity. The incidence and pattern of AEs were generally similar in the <NUM> treatment groups, Table <NUM>.

Eight subjects had TEAEs assessed as related to study drug; two in the CXA-<NUM> group (diarrhea and somnolence in <NUM> subject each) and six in the piperacillin/tazobactam group (diarrhea in <NUM> subjects, type I hypersensitivity in <NUM> subject, blood creatine phosphokinase increased in <NUM> subject, and alanine aminotransferase increased, aspartate aminotransferase increased, and hyperkalaemia all in the same <NUM> subject). One piperacillin/tazobactam-treated subject discontinued study drug due to an adverse event, type I hypersensitivity. There were no clinically significant changes in safety laboratory assessments or vital signs.

CXA-<NUM> appeared safe and well tolerated in this group of healthy adult subjects.

A Monte Carlo simulation was performed based on clinical trial data to predict an effective CXA-<NUM> dose for treating nosocomial pneumonia using PHOENIX® NLME (PHARSIGHT®, Mountain View, CA) software, a tool for data processing and modeling for population PK/PD analysis. A population pharmacokinetic (PK) model was developed using the CXA-<NUM> plasma concentration versus time data from a previously conducted Phase <NUM> study in patients with complicated intra abdominal infections. Estimates of clearance and volume of distribution along with the associated inter-individual variability were obtained from these analyses. The outputs from the PK population model served as inputs for a clinical trial simulation performed using PHARSIGHT® Trial Simulator (PHARSIGHT®) software, a tool for defining and testing interactive drug models, exploring and communicating study design attributes, and performing statistical and sensitivity analysis through graphical and statistical summaries. Based on the mean ELF penetration data, an ELF/Plasma AUC ratio of <NUM> for ceftolozane (modeled as a numerical range of <NUM>-<NUM>) calculated from the ceftolozane ELF study mentioned above was used to generate a random /Plasma AUC ratio from the range <NUM> - <NUM> for each simulated patient. This range reflects a conservative estimate of the potential distribution in a patient population. Using the results from the PK population model and the ELF/Plasma AUC ratio, the model simulated plasma and ELF concentration of CXA-<NUM> versus time profiles for <NUM>,<NUM> hypothetical clinical trial patients with nosocomial pneumonia. The model evaluated the probability of clinical success of the <NUM> every <NUM> hour (q8h) dose of CXA-<NUM> against three key pathogens in nosocomial pneumonia. The MIC distribution for these pathogens was imputed from <NUM> United States surveillance data. Clinical success was defined as the achievement of an ELF or plasma concentration of ceftolozane higher than the MIC(s) of the lower respiratory pathogen(s) for a given patient. In vivo models have demonstrated that, as for typical cephlaosporins, the relavent PK/PD driver for CXA-<NUM> is the percentage of time above MIC during the dosing interval. The target is to achieve concentrations that exceed the MIC of the pathogen for <NUM>-<NUM>% of the time between each q8H dose. Thus, a threshold of <NUM>% time above the minimum inhibitory concentration [T>MIC] on Day <NUM> of treatment was used. Plasma and ELF concentrations were estimated at <NUM> time-points post-administration on Day <NUM> when dosed every <NUM> hours. The results of these simulations are shown in Table <NUM>.

These simulations demonstrate that the <NUM> dose of CXA-<NUM> administered every <NUM> hours is expected to provide adequate concentrations for treatment of the vast majority of lower respiratory infections caused by these pathogens.

Following these simulations, the safety and tolerability of a <NUM> day course of CXA-<NUM><NUM> IV q8h was evaluated in healthy human volunteers. Subjects were randomized to receive either <NUM> (<NUM>/<NUM>) CXA-<NUM> (n=<NUM>), <NUM> (<NUM>/<NUM>) CXA-<NUM> (n=<NUM>), or placebo (n=<NUM>). The data showed that CXA-<NUM> was generally safe and well tolerated in this study. There were no serious adverse events or deaths reported in this study.

In conclusion, given the pharmacokinetic simulations conducted, the favorable data from the intrapulmonary PK study and demonstrated safety and tolerability of the higher dose of CXA-<NUM> in the Phase <NUM> study mentioned above, the data provide justification for the use of <NUM> CXA-<NUM> IV q8h for the treatment of patients with nosocomial pneumonia caused by Gram-negative pathogens.

CXA-<NUM> can be prepared by combining ceftolozane and tazobactam in a <NUM>:<NUM> weight ratio. CXA-<NUM> can be obtained using methods described in <CIT> and <NPL>).

According to the method disclosed in <NPL>), ceftolozane can be obtained by the synthetic schemes of <FIG> and <FIG>. Referring to <FIG> and <FIG>, synthesis of ceftolozane can be performed via activation of the thiadiazolyl-oximinoacetic acid derivative (I) with methanesulfonyl chloride and K<NUM>CO<NUM> in DMA at <NUM>, followed by coupling with the <NUM>-aminocephem (II) by means of Et<NUM>N in cold EtOAc/H<NUM>O, affords amide (III) (<NUM>). Substitution of the allylic chloride of compound (III) with <NUM>-[(N-Boc-aminoethyl)carbamoylamino]-<NUM>-methyl-<NUM>-tritylaminopyrazole (IV) in the presence of <NUM>,<NUM>-bis(trimethylsilyl)urea (BSU) and KI in DMF then affords the protected pyrazolium adduct (V), which, after full deprotection with trifluoroacetic acid in anisole/CH<NUM>Cl<NUM>,can be isolated as the hydrogensulfate salt by treatment with H2SO4 in i-PrOH/H<NUM>O (<NUM>, <NUM>). Scheme <NUM>. The pyrazolyl urea intermediate (IV) can be prepared as follows. Treatment of <NUM>-amino-<NUM>-methylpyrazole (VI) with NaNO<NUM>/HCl in water at <NUM> gives the <NUM>-nitrosopyrazole derivative (VII), which can be reduced to the diaminopyrazole (VIII) by catalytic hydrogenation over Pd/C in the presence of H<NUM>SO<NUM>. Selective acylation of the <NUM>-amino group of compound (VIII) with phenyl chloroformate in the presence of NaOH in H<NUM>O/dioxane at <NUM> then yields the phenyl carbamate (IX). After protection of the free amine group of carbamate (IX) with chlorotriphenylmethane in the presence of Et<NUM>N in THF, the resulting N-trityl derivative (X)can be coupled with N-Boc-ethylenediamine (XI) in the presence of Et<NUM>N in DMF to afford pyrazolyl urea (IV).

The antibacterial activity of the CXA-<NUM> or other compounds can be measured by the minimum inhibitory concentrations (MIC) of the compounds against various bacteria measured by using the broth microdilution method performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines with modifications as described below (CLSI guidelines can be derived from the<NPL>on").

To prepare for MIC testing, individual colonies can be isolated by streaking frozen glycerol material containing Staphylococcus or Pseudomonas spp. onto rich, non-selective, tryptic soy agar containing <NUM>% sheep's blood (TSAB), and incubated at <NUM> for <NUM>-<NUM> hrs.

On the day of testing, primary cultures can be started by scraping off <NUM>-<NUM> colonies from the TSAB plates. The material can be suspended in ~<NUM> of cation adjusted Mueller Hinton Broth (CAMHB) in <NUM> culture tubes and can be incubated at <NUM> with aeration (<NUM> rpm) for ~<NUM> hrs until the OD600 was ≥<NUM>.

Inoculum cultures can be prepared by standardizing the primary cultures to OD600 = <NUM> and then adding <NUM>µL of the adjusted primary culture per <NUM> CAMHB for Pseudomonas and CAMHB plus <NUM>% NaCl for MRSA so that the final inoculum density was ~<NUM><NUM> colony forming units per milliliter. Diluted inoculum cultures can be used to inoculate <NUM>µL per well in <NUM> well broth microdilution assay plates. <NUM>µL of CAMHB that contained compound concentrations ranging from <NUM> - <NUM>µg/mL in two-fold dilutions can also be added to the broth microdilution assay plates for a final volume <NUM>µL per well, therefore final culture OD<NUM> was approximately <NUM> and the final NaCl concentration for the MRSA strain was <NUM>%.

Claim 1:
Ceftolozane (CXA-<NUM>) and tazobactam in a <NUM>:<NUM> (ceftolozane:tazobactam) weight ratio at a dose of <NUM> for use in a method of treating nosocomial pneumonia caused by Gram-negative pathogens in a human, wherein the ceftolozane and tazobactam is administered intravenously once every <NUM> hours, and wherein the ceftolozane is in its free-base form or in its salt form.